DEFA14A: Enzo Biochem to Be Acquired by Battery Ventures for $37 Million in Cash

Enzo Biochem, Inc. has entered into a definitive agreement to be acquired by an affiliate of Battery Ventures for $0.70 per share in cash, totaling approximately $37 million.

Summary

• Enzo Biochem, Inc. (Enzo) has agreed to be acquired by Bethpage Parent, Inc., an affiliate of Battery Ventures, following a comprehensive review of value-maximizing alternatives by a special committee of Enzo's Board of Directors.
• Under the terms of the Agreement and Plan of Merger, Battery Ventures will acquire Enzo for $0.70 per share in cash.
• The total consideration for the acquisition is approximately $37 million.
• The Merger Agreement was dated June 23, 2025, and communications regarding the transaction were first made available on June 24, 2025.
• The transaction is subject to customary closing conditions, including shareholder approval.
• Closing of the transaction is expected in the third quarter of the current calendar year.
• A press release announcing the transaction was issued, and a Form 8-K with additional information was filed with the SEC.
• A proxy statement will be filed with the SEC and mailed to shareholders, providing further details on the transaction.

Sentiment

Score: 8

Explanation: The document announces a definitive merger agreement resulting from a strategic review, presented by management as an exciting next chapter. While standard merger risks are disclosed, the overall tone is positive regarding the completion of a value-maximizing process.

Positives

• The acquisition provides a clear exit strategy and liquidity for shareholders at a defined cash price of $0.70 per share.
• The transaction is the result of a comprehensive review of value-maximizing alternatives, suggesting it is considered beneficial by the company's special committee and management.
• The acquisition by Battery Ventures, a global, technology-focused investment firm, could provide new strategic direction and resources for Enzo.

Negatives

• The acquisition price of $0.70 per share may be lower than some shareholders' expectations or historical stock prices, potentially leading to dissatisfaction.
• The transaction involves significant transaction costs and potential unknown or inestimable liabilities.
• There is a risk of shareholder litigation in connection with the merger, which could result in additional expense or delay.

Risks

• The ability of Enzo and Parent to complete the Merger on the proposed terms or anticipated timeline, or at all, is not guaranteed.
• Securing the necessary approval of Enzo's shareholders is a condition for closing.
• Compliance with the covenants contained in the Merger Agreement is required.
• Satisfaction of other closing conditions is necessary to consummate the Merger.
• The occurrence of any event, change, or other circumstance could give rise to the termination of the definitive transaction agreement.
• Diverting the attention of Enzo's management from ongoing business operations poses a risk.
• Significant transaction costs and/or unknown or inestimable liabilities are potential financial risks.
• The risk of shareholder litigation in connection with the Merger, including resulting expense or delay, is present.
• Other risks and uncertainties affecting the Company are described under the caption 'Risk Factors' in Enzo's Annual Report on Form 10-K for the fiscal year ended July 31, 2024, and other public filings.

Future Outlook

The transaction is expected to close in the third quarter of the current calendar year, subject to customary closing conditions, including shareholder approval. The company anticipates filing a proxy statement with the SEC, which will be mailed to shareholders.

Management Comments

• Kara Cannon, Chief Executive Officer of Enzo: "I am very excited about this next chapter for Enzo."

Industry Context

NA

Legal Proceedings

• Risk of shareholder litigation in connection with the Merger, including resulting expense or delay.

Stakeholder Impact

• Shareholders: Will receive $0.70 per share in cash upon completion of the merger.
• Employees: Management's attention may be diverted from ongoing business operations due to the merger process.
• Management: Will be focused on completing the merger, potentially diverting attention from day-to-day operations.

Next Steps

• Filing of a proxy statement with the SEC.
• Mailing of the final proxy statement to all shareholders of Enzo.
• Shareholder approval of the transaction.
• Satisfaction of all customary closing conditions.
• Closing of the transaction, expected in the third quarter of the calendar year.

Key Dates

Keywords

Enzo Biochem, Battery Ventures, Merger, Acquisition, SEC filing, DEFA14A, Shareholder approval, Cash acquisition, Corporate transaction, Biotech acquisition